Periprocedural outcomes from the postmarket study of the extravascular implantable cardioverter-defibrillator: Preliminary Enlighten study results and meta-analysis
Authors:
- 2 April 2025
- journal article
- Published by Elsevier in Heart Rhythm
- Vol. 23 (1) , 180-185
Abstract
No abstract availableKeywords
Funding Information
- Medtronic
This publication has 14 references indexed in Scilit:
- Design of a post-market registry for the extravascular implantable cardioverter-defibrillator: The Enlighten StudyHeart Rhythm O2, 2024
- Efficacy and Safety of an Extravascular Implantable Cardioverter–DefibrillatorNew England Journal of Medicine, 2022
- Survival After Implantable Cardioverter-Defibrillator ShocksJACC, 2021
- First-in-Human Chronic Implant Experience of the Substernal Extravascular Implantable Cardioverter-DefibrillatorJACC: Clinical Electrophysiology, 2020
- Subcutaneous or Transvenous Defibrillator TherapyNew England Journal of Medicine, 2020
- Incidence, predictors, and outcomes associated with pneumothorax during cardiac electronic device implantation: A 16-year review in over 3.7 million patientsHeart Rhythm, 2017
- Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative resultsHeart Rhythm, 2017
- Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD RegistryEuropean Heart Journal, 2014
- Reduction in Inappropriate Therapy and Mortality through ICD ProgrammingNew England Journal of Medicine, 2012
- Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart FailureNew England Journal of Medicine, 2005